Thursday, September 02, 2021 8:10:24 AM
XPro news also impressive. Data very.
“The data from this Phase I trial show that XPro decreases biomarkers of neuroinflammation and nerve cell death while improving biomarkers of neurorepair in patients with AD,” stated RJ Tesi, M.D., CEO of INmune Bio
“The data from this Phase I trial show that XPro decreases biomarkers of neuroinflammation and nerve cell death while improving biomarkers of neurorepair in patients with AD,” stated RJ Tesi, M.D., CEO of INmune Bio
Recent INMB News
- INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform • GlobeNewswire Inc. • 05/15/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 08:05:34 PM
- INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease • GlobeNewswire Inc. • 05/14/2026 12:00:00 PM
- INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point • GlobeNewswire Inc. • 05/13/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:17:07 PM
- INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update • GlobeNewswire Inc. • 05/07/2026 08:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:30:19 PM
- INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases • GlobeNewswire Inc. • 05/05/2026 08:00:00 PM
- INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th • GlobeNewswire Inc. • 04/30/2026 12:00:00 PM
- INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models • GlobeNewswire Inc. • 04/16/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:29:24 PM
- INmune Bio Inc. Announces 2025 Results and Provides Business Update • GlobeNewswire Inc. • 03/30/2026 08:00:00 PM
- INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. • GlobeNewswire Inc. • 03/24/2026 12:00:00 PM
- INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2026 02:14:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:05:29 PM
- INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar • GlobeNewswire Inc. • 02/23/2026 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 09:00:25 PM
- INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB • GlobeNewswire Inc. • 02/19/2026 05:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 09:00:31 PM
- INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease • GlobeNewswire Inc. • 02/12/2026 12:00:00 PM
- INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB • GlobeNewswire Inc. • 02/10/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/27/2026 09:00:38 PM
- INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives • GlobeNewswire Inc. • 01/27/2026 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 09:00:32 PM
